Objective To investigate the detection results of GHB with different instruments, and to provide reliable basis for improving the accuracy of GHB detection. Methods ADVIA 1650 biochemical analyzer and HA-8160 glycosylated hemoglobin analyzer were used. The accurate detection of glycosylated hemoglobin in 100 healthy people was carried out, and the related data were recorded and analyzed statistically. Attention should be paid to this group according to glycosylated hemoglobin detection value, that is, within 6.5％ for A group, 6.5％-10.0％ for B group, more than 10％ for C group, and compare the above-mentioned different grouping of corresponding instrument glycosylated hemoglobin detection value. Results The analysis showed that there was no significant difference between the two groups of C instrument glycosylated hemoglobin levels, but the level of glycosylated hemoglobin detected by A in group HA-8160 and group B was significantly higher than that of ADVIA 1650(P<0.05). Conclusion Different instruments have some differences in the detection value of glycosylated hemoglobin. Clinicians should judge the disease comprehensively according to the actual situation and other indicators.

Parkinson's disease (PD) is a chronic neurodegenerative disease. At present, levodopa and other drugs are mainly used for dopamine supplementation therapy. However, the absorption of levodopa in the gastrointestinal tract is unstable and its half-life is short, and long-term use of levodopa will lead to the end-of-dose deterioration, dyskinesia, the "ON-OFF" phenomenon and other symptoms. Therefore, new preparations need to be developed to improve drug efficacy, reduce side effects or improve compliance of patients. Based on the above clinical needs, this review briefly introduced the preparation modification strategies for the treatment of PD through case analysis, in order to provide references for the research and development of related preparations.